DURECT (NASDAQ:DRRX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of DURECT (NASDAQ:DRRX) in a report issued on Tuesday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of DURECT in a research note on Thursday, November 14th.

DURECT Stock Up 17.1 %

DRRX stock opened at $1.01 on Tuesday. The company has a market cap of $31.35 million, a PE ratio of -1.66 and a beta of 1.13. The business has a 50-day simple moving average of $1.30 and a 200 day simple moving average of $1.36. DURECT has a 52 week low of $0.48 and a 52 week high of $1.88.

Institutional Trading of DURECT

Several institutional investors have recently added to or reduced their stakes in the stock. International Assets Investment Management LLC boosted its holdings in DURECT by 41.3% in the second quarter. International Assets Investment Management LLC now owns 21,550 shares of the specialty pharmaceutical company’s stock valued at $28,000 after acquiring an additional 6,300 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of DURECT by 4.8% during the 3rd quarter. Geode Capital Management LLC now owns 319,905 shares of the specialty pharmaceutical company’s stock worth $429,000 after buying an additional 14,658 shares in the last quarter. Accredited Investors Inc. bought a new position in shares of DURECT during the 2nd quarter worth approximately $113,000. Finally, Richmond Brothers Inc. boosted its holdings in shares of DURECT by 39.5% during the 2nd quarter. Richmond Brothers Inc. now owns 1,072,014 shares of the specialty pharmaceutical company’s stock worth $1,383,000 after buying an additional 303,670 shares in the last quarter. 28.03% of the stock is currently owned by institutional investors.

About DURECT

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.